logo

Imetelstat update


Imetelstat is currently in two clinical trials which were originally conducted by Janssen Research and Development ( Janssen) under a collaboration agreement ( see Partners). Mar 19, · Geron ( NASDAQ: GERN) is up 35% premarket on modest volume in apparent reaction to its update on a mid- stage study assessing imetelstat in treatment- resistant patients with lower- risk. Geron will host a conference call to discuss the imetelstat program update at 9: 00 a.

Imetelstat is currently being tested in two clinical trials: IMbark, a Phase 2 trial in myelofibrosis ( MF), and IMerge, a Phase 2/ 3 trial in myelodysplastic syndromes ( MDS). Federal Government. May 16, · Geron will host a conference call to discuss the imetelstat program update at 9: 00 a. “ is off to a good. IMerge Part 1 is a Phase 2, open- label, single- arm trial of imetelstat administered as a single agent by intravenous infusion, and is ongoing.
Imetelstat ( GRN163L; JNJis a potent and specific inhibitor of telomerase that is administered by intravenous infusion. “ is off to a good start with the imetelstat IND transfer now complete. Listing a study does not mean it has been evaluated by the U. Sep 14, · Geron was betting the farm on imetelstat’ s successful challenge to JAK2 inhibitors in the myelofibrosis space. Jul 31, · About Imetelstat.

Jul 09, · Forum permissions. You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum. May 16, · The second press release was an Imetelstat Program Update announcing the transfer of the Imetelstat IND sponsorship from Janssen to Geron. ET on Thursday, May 16,, which will also include a. ET on Thursday, May 16,, which will also include a discussion of future presentations of imetelstat clinical data. This first- in- class compound, discovered by Geron, is a specially designed and modified short oligonucleotide, which targets and binds directly with high affinity to the active site of telomerase.
Nov 22, · Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. , May 16, ( GLOBE NEWSWIRE) - - Geron Corporation ( Nasdaq: GERN) today provided an update to its corporate objectives for the imetelstat program. May 16, · Geron Corporation ( GERN) today provided an update to its corporate objectives for the imetelstat program. May 16, · MENLO PARK, Calif.


Imetelstat, a first- in- class telomerase inhibitor and our sole product candidate, is being developed for the potential treatment of hematologic myeloid malignancies. It was a bold strategic move and, given the unproven efficacy of imetelstat, the long testing and approval process ahead and the deeply entrenched position of competition, a long shot. The purpose of imetelstat. Participants may access the conference call live via telephone by dialing domesticallyor internationally. Imetelstat update. In that press release, we also provided updates to.
Info is to provide easy access to existing information about imetelstat, its basic workings,. ET on Thursday, May 16,, which will also include a discussion of future presentations of imetelstat. Quick steps on the way to ASH. Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely.

Phone:(754) 326-6617 x 2359

Email: [email protected]